1. Home
  2. NTRA vs AME Comparison

NTRA vs AME Comparison

Compare NTRA & AME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$272.94

Market Cap

56.7B

Sector

Health Care

ML Signal

N/A

Logo AMETEK Inc.

AME

AMETEK Inc.

N/A

Current Price

$222.87

Market Cap

57.0B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
NTRA
AME
Founded
2003
1930
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
56.7B
57.0B
IPO Year
2015
1998

Fundamental Metrics

Financial Performance
Metric
NTRA
AME
Price
$272.94
$222.87
Analyst Decision
Strong Buy
Buy
Analyst Count
23
20
Target Price
★ $412.36
$288.83
AVG Volume (30 Days)
★ 2.0M
1.5M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
★ 0.59%
EPS Growth
0.65
★ 7.93
EPS
N/A
★ 5.36
Revenue
$210,939,000.00
★ $7,401,116,000.00
Revenue This Year
$30.72
$16.33
Revenue Next Year
$21.67
$15.16
P/E Ratio
★ N/A
$43.13
Revenue Growth
N/A
★ 6.63
52 Week Low
$181.00
$194.01
52 Week High
$437.41
$261.16

Technical Indicators

Market Signals
Indicator
NTRA
AME
Relative Strength Index (RSI) 24.66 35.64
Support Level $254.83 $207.79
Resistance Level $288.04 $240.83
Average True Range (ATR) 19.03 7.52
MACD -7.70 -1.07
Stochastic Oscillator 1.47 4.40

Price Performance

Historical Comparison
NTRA
AME

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About AME AMETEK Inc.

Founded in 1930 and transformed over the decades through the acquisition of dozens of esteemed brands, Ametek owns more than 40 autonomous industrial businesses operating across research, aerospace, energy, medical, and manufacturing. Ametek segments its business into two operating groups: the electronic instruments group and the electromechanical group. The EIG sells a broad portfolio of analytical, test, and measurement instruments, while the EMG sells highly engineered components, interconnects, and specialty metals. The company emphasizes product differentiation and market leadership in the niche markets it operates in.

Share on Social Networks: